Abiraterone Acetate: all 143 studies that test it

Page 2 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate CancerTerminatedNCT03360721Phase 2
• Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the ProstateStatus unknownNCT03356444Phase 2
• Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaStatus unknownNCT03145285Phase 2
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerActive, not recruitingNCT03016741Phase 4
• Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsActive, not recruitingNCT03012321Phase 2
• A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerCompletedNCT03009981Phase 3
• A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)CompletedNCT02924766Phase 1
• Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPCCompletedNCT02913196Phase 1
• Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland CancersCompletedNCT02867852Phase 2
• Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerActive, not recruitingNCT02807805Phase 2
• Abiraterone-Rechallenge Study for CRPC PatientsTerminatedNCT02656615Phase 2
• Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate CancerCompletedNCT02415621Early Phase 1
• A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade TherapyCompletedNCT02405858Phase 4
• Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male ParticipantsCompletedNCT02230046Phase 1
• Neo-adjuvant Abiraterone Prostate StudyCompletedNCT02160353Phase 2
• A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyWithdrawnNCT02159690Phase 2
• Sequencing Abiraterone and Enzalutamide in mCRPCCompletedNCT02125357Phase 2
• A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02123758Phase 1
• Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)CompletedNCT02077634Phase 2
• A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic FunctionCompletedNCT02001571Phase 1
• A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerActive, not recruitingNCT01957436Phase 3
• Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedNCT01913015Phase 1
• A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male ParticipantsCompletedNCT01873001Phase 1
• Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone AcetateCompletedNCT01858441Not applicable
• Abiraterone Acetate in Molecular Apocrine Breast CancerCompletedNCT01842321Phase 2
• Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast CancerWithdrawnNCT01814865Phase 2
• A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male PatientsCompletedNCT01798628Phase 1
• Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateCompletedNCT01792687Phase 1
• Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerActive, not recruitingNCT01786265Phase 2
• A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal FunctionCompletedNCT01715259Phase 1
• A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone AcetateCompletedNCT01685268Phase 1/2
• A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male ParticipantsCompletedNCT01678573Phase 1
• An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001CompletedNCT01664728Phase 1
• A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male ParticipantsCompletedNCT01655147Phase 1
• A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial TabletCompletedNCT01640093Phase 1
• Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate CancerCompletedNCT01591122Phase 3
• A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase DeficiencyCompletedNCT01495910Phase 1
• A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult VolunteersCompletedNCT01362764Phase 1
• Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate CancerCompletedNCT01186484Phase 1
• A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01017939Phase 1
• A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT00910754Phase 1
• Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerCompletedNCT00755885Phase 1/2
• A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate CancerCompletedNCT00600535Phase 1

← Abiraterone Acetate overview